Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2421-2424

  Krueger, W A ^a,c   Schroeder, T H ^a   Hutchison, M ^b   Hoffmann, E ^a   Dieterich, H J ^a   Heininger, A ^a   Erley, C ^a   Wehrle, A ^a   Unertl, K ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ASTRAZENECA   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HEMODIALYSIS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0031713715     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2421     Document Type: Article

References (24)

1. Allen, G. D. 1990. MODFIT. A pharmacokinetic computer program. Biopharm. Drug Dispos. 11:477-498.
2. Bax, R. P., W. Bastain, A. Featherstone, D. M. Wilkinson, M. Hutchison, and S. J. Haworth. 1989. The pharmacokincties of meropenem in volunteers. J. Antimicrob. Chemother. 24(Suppl. A):311-320.
3. Bedikian A., M. P. Okamoto, R. K. Nakahiro, J. Farino, P. N. R. Heseltine, M. D. Appleman, A. E. Yellin, T. V. Berne, and M. A. Gill. 1994. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob. Agents Chemother. 38:151-154.
4. Burman, L. A., I. Nilsson-Ehle, M. Hutchison, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother. 27:219-224.
5. Chimata, M., M. Nagase, Y. Suzuki, M. Shimomura, and S. Kakuta. 1993. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob. Agents Chemother. 37:229-233.
6. Christensson, B. A., I. Nilsson-Ehle, M. Hutchison, S. J. Haworth, B. Öqvist, and S. R. Norrby. 1992. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob. Agents Chemother. 36: 1532-1537.
7. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
8. Edwards, J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36(Suppl. A):1-17.
9. Fukasawa, M., Y. Sumita, E. T. Harabe, T. Tanio, H. Nouda, T. Kohzuki, T. Okuda, H. Matsumura, and M. Sunagawa. 1992. Stability of meropenem and the effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.
10. Golper, T. A. 1985. Continuous arteriovenous hemofiltration in acute renal failure. Am. J. Kidney Dis. 6:373-386.
11. Harrison, M. P., S. R. Moss, A. Featherstone, A. G. Fowkes, A. M. Sanders, and D. E. Case. 1989. The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother. 24(Suppl. A):265-277.
12. 14C-meropenem in man. Xenobiotica 23:1311-1323.
13. Hutchison, M. Personal communication.
14. Kelly, H. C., M. Hutchison, and S. J. Haworth. 1995. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J. Antimicrob. Chemother. 36(Suppl. A):35-41.
15. Leroy, A., J. P. Fillastre, F. Borsa-Lebas, I. Etienne, and G. Humbert. 1992. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob. Agents Chemother. 36:2794-2798.
16. Mehtar, S., E. P. Dewar, D. J. Leaper, and E. W. Taylor. 1997. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J. Antimicrob. Chemother. 39:631-638.
17. Mouton, Y. J., C. Beuscart, and the Meropenem Study Group. 1995. Empirical monotherapy with meropenem in serious bacterial infections. J. Antimicrob. Chemother. 36(Suppl. A):145-156.
18. Nilsson-Ehle, I., M. Hutchison, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10:85-88.
19. Norrby, S. R., P. A. Newell, K. L. Faulkner, and W. Lesky. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother. 36(Suppl. A):207-223.
20. Reetze-Bonorden, P., J. Böhler, and E. Keller. 1993. Drug dosage in patients during continuous renal replacement therapy. Clin. Pharmacokinet. 24:362-379.
21. Schroeder, T. H., M. Hansen, E. Hoffmann, and W. A. Krueger. 1997. Simulation der Pharmakokinetik von Meropenem bei kontinuierlichen Nierenersatzverfahren in vitro, abstr. FV 30.5. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 32(Suppl. 1):S162.
22. Sörgel, F., K. G. Naber, A. Bauernfeind, M. Kinzig-Schippers, H. Schuhmacher, G. Rüsing, and A. Bergmann. 1997. Pharmacokinetics and pharmacodynamics of meropenem after intermittent and continuous infusion in healthy volunteers, abstr. A-49, p. 10. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
24. Walker, R., D. Andes, R. Conklin, S. Ebert, and W. Craig. 1994. Pharmacodynamic activities of meropenem in an animal infection model, abstr. A91, p. 147. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.